T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer

Journal of Medical Virology

Volumn 83, Issue 6, 2011, Pages 1023-1030

  Chan, Paul K S ^a   Liu, Shih Jen ^b,c   Cheung, Jo L K ^a   Cheung, T H ^a   Yeo, Winnie ^a   Chong, Pele ^b   Man, Stephen ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cervical cancer; HPV 52; T cell epitope; T cell response; Therapeutic vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; GENOMIC DNA; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HUMAN PAPILLOMAVIRUS E6 PPROTEIN; HUMAN PAPILLOMAVIRUS E7 PPROTEIN; HUMAN PAPILLOMAVIRUS L1 PPROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 52; IMMUNE EVASION; IMMUNE RESPONSE; INFECTION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TRANSIENT INFECTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS IMMUNITY;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DNA, VIRAL; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A11 ANTIGEN; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PEPTIDES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 52; PAPILLOMAVIRIDAE;

EID: 79954578372     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21889     Document Type: Article

References (47)

1. Alvarez-Salas LM. 2008. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr Opin Mol Ther 10:622-628.
2. Bao YP, Li N, Smith JS, Qiao YL, ACCPAB Members. 2008. Human papillomavirus type distribution in women from Asia: A meta-analysis. Int J Gynecol Cancer 18:71-79.
3. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. 2008. A meta-analysis of human papillomavirus type-distribution in women from South Asia: Implications for vaccination. Vaccine 26:2811-2817.
4. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, Walboomers JM. 2000. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 88:92-98.
5. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M. 2006. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118:243-245.
6. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung TH, Wong MC, To KF, Ng HK. 2009a. Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades. Int J Cancer 125:1671-1677.
7. Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK. 2009b. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 44:111-114.
8. Chen HW, Leng CH, Liu HY, Cheng WF, Chang YW, Wu PY, Lien SP, Huang TY, Chiang SK, Lin MH, Tao MH, Chong P, Liu SJ. 2009. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther 21:2025-2032.
9. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88:63-73.
10. Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110:525-541.
11. Evans C, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, Wagner H, Lipford GB. 1996. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 42:151-160.
12. Franco EL, Rohan TE, Villa LL. 1999. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91:506-511.
13. Frieden TR, Myers JE, Krauskopf MS, Farley TA. 2008. A public health approach to winning the war against cancer. Oncologist 13:1306-1313.
14. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927.
15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943.
16. Gillison ML, Chaturvedi AK, Lowy DR. 2008. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113:3036-3046.
17. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX. 2008. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26:K17-K28.
18. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. HPV Vaccine Study Group. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367:1247-1255.
19. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. 2006. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 102:54-60.
20. Huang S, Afonina I, Miller BA, Beckmann AM. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70:408-411.
21. Hung CF, Monie A, Alvarez RD, Wu TC. 2007. DNA vaccines for cervical cancer: From bench to bedside. Exp Mol Med 39:679-689.
22. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 19:1838-1847.
23. Michelin MA, Murta EF. 2008. Potential therapeutic vaccine strategies and relevance of the immune system in uterine cervical cancer. Eur J Gynaecol Oncol 29:10-18.
24. Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, van den Eertwegh AJ, Scheper RJ, von Blomberg ME, Bontkes HJ. 2007. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121:1749-1755.
25. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416.
26. Muñoz N. 2000. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 19:1-5.
27. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cancer. N Engl J Med 348:518-527.
28. Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. 2009. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373:1949-1957.
29. Narayan S, Choyce A, Linedale R, Saunders NA, Dahler A, Chan E, Fernando GJ, Frazer IH, Leggatt GR. 2009. Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+ CD25+ T cells. Eur J Immunol 39:481-490.
30. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 57:4855-4861.
31. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
32. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
33. Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA, Coleman N. 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 64:1359-1368.
34. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJ. 1996. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 56:582-588.
35. Sasagawa T, Basha W, Yamazaki H, Inoue M. 2001. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 10:45-52.
36. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 17:167-176.
37. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta analysis update. Int J Cancer 121:621-632.
38. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. 2009. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15:361-367.
39. Valdespino V, Gorodezky C, Ortiz V, Kaufmann AM, Roman-Basaure E, Vazquez A, Berumen J. 2005. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol 96:92-102.
40. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612-618.
41. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. 2007. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 104:12087-12092.
42. Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, van der Zee AG, Daemen T. 2007. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 150:199-209.
43. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
44. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH. 2008. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178-187.
45. Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, Kwappenberg KM, Stanley MA, van der Burg SH. 2010. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer 1:133-141.
46. zur Hausen H. 2002. Papillomavirus and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.
47. zur Hausen H. 2009. Papillomaviruses in the causation of human cancers-A brief historical account. Virology 384:260-265.